AR018501A1 - Derivados de la dolastatina 15 - Google Patents

Derivados de la dolastatina 15

Info

Publication number
AR018501A1
AR018501A1 ARP980103445A ARP980103445A AR018501A1 AR 018501 A1 AR018501 A1 AR 018501A1 AR P980103445 A ARP980103445 A AR P980103445A AR P980103445 A ARP980103445 A AR P980103445A AR 018501 A1 AR018501 A1 AR 018501A1
Authority
AR
Argentina
Prior art keywords
group
amino
formula
present
amino group
Prior art date
Application number
ARP980103445A
Other languages
English (en)
Original Assignee
Abbott Gmbh & Co Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Gmbh & Co Kg filed Critical Abbott Gmbh & Co Kg
Publication of AR018501A1 publication Critical patent/AR018501A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

Los compuestos incluyen inhibidores del crecimiento celular que consisten en péptidos de Formula (I) A - B - D - E - F -(G)r - (K)s -L y sus sales deácidos correspondientes, donde A, B, D. E, F, G y K son residuos de alfa-aminoácidos,y s y r valen,i ndependientemente, 0 o 1. L es un radical monovalente,como por ejemplo un grupo amino, un grupo amino N-sustituido, un grupo beta-hidroxilamino, un grupo hidrazido, un grupo alcoxi, un grupo tioalcoxi, un grupoaminoxi o un grupo oximato. Lapresente invencion incluye asimismo un método para el tratamiento del cáncer en mamíferos, como un ser humano, que implica laadministracion al mamífero de una dosis efectiva de un compuesto de Formula I presente en una composicion farmacéuticamenteaceptable.
ARP980103445A 1997-07-18 1998-07-15 Derivados de la dolastatina 15 AR018501A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/896,394 US6143721A (en) 1997-07-18 1997-07-18 Dolastatin 15 derivatives

Publications (1)

Publication Number Publication Date
AR018501A1 true AR018501A1 (es) 2001-11-28

Family

ID=25406130

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP980103445A AR018501A1 (es) 1997-07-18 1998-07-15 Derivados de la dolastatina 15

Country Status (33)

Country Link
US (6) US6143721A (es)
EP (1) EP0991658B1 (es)
JP (4) JP4508413B2 (es)
KR (1) KR100579748B1 (es)
CN (1) CN1268636C (es)
AR (1) AR018501A1 (es)
AT (1) ATE314387T1 (es)
AU (1) AU750120B2 (es)
BG (1) BG65212B1 (es)
BR (1) BR9810911A (es)
CA (1) CA2296036C (es)
CO (1) CO4990967A1 (es)
CY (1) CY1107047T1 (es)
CZ (1) CZ303045B6 (es)
DE (1) DE69832982T2 (es)
DK (1) DK0991658T3 (es)
ES (1) ES2258819T3 (es)
HK (1) HK1029125A1 (es)
HR (1) HRP980397A2 (es)
HU (1) HU228996B1 (es)
ID (1) ID24669A (es)
IL (1) IL133784A (es)
MY (1) MY135057A (es)
NO (1) NO326827B1 (es)
NZ (1) NZ502296A (es)
PL (1) PL197884B1 (es)
PT (1) PT991658E (es)
RU (1) RU2195462C2 (es)
SK (1) SK286581B6 (es)
TR (2) TR200103545T2 (es)
TW (1) TW533217B (es)
WO (1) WO1999003879A1 (es)
ZA (1) ZA986358B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
AU2001227375A1 (en) * 2000-02-08 2001-08-20 Herbert T. Nagasawa N-terminal d(-)-penicillamine peptides as aldehyde sequestration agents
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
NZ535139A (en) 2002-03-22 2007-07-27 Eisai Co Ltd Hemiasterlin derivatives and uses thereof in the treatment of cancer
EP2357006B1 (en) 2002-07-31 2015-09-16 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
BR122018071968B8 (pt) 2003-11-06 2021-07-27 Seattle Genetics Inc conjugado de anticorpo-droga, composição farmacêutica, artigo de manufatura e uso de um conjugado de anticorpo-droga
EP1828776A4 (en) * 2004-12-09 2010-03-17 Eisai R&D Man Co Ltd TUBULINISOTYPE SEARCH IN CANCER THERAPY WITH HEMIASTERLINANALOGES
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
CA2692819A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
PE20140614A1 (es) 2007-07-16 2014-05-28 Genentech Inc Anticuerpos anti-cd79b e inmunoconjugados
DE102007039706A1 (de) 2007-08-22 2009-02-26 Erhard Prof. Dr.-Ing. Kohn Chemischer Sensor auf Diamantschichten
SI2247620T1 (sl) 2008-01-31 2016-09-30 Genentech, Inc. Protitelesa proti CD79b in imunokonjugati in postopki za uporabo
MY159958A (en) * 2009-12-18 2017-02-15 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
AU2011215900A1 (en) 2010-02-10 2012-07-26 Immunogen, Inc. CD20 antibodies and uses thereof
WO2011098904A1 (en) 2010-02-12 2011-08-18 Aegera Therapeutics, Inc. Iap bir domain binding compounds
JP6133431B2 (ja) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー．，エルティディ．Ｈａｎｇｚｈｏｕ Ｄａｃ Ｂｉｏｔｅｃｈ Ｃｏ．，Ｌｔｄ． 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
EP3689910A3 (en) 2014-09-23 2020-12-02 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
AU2015242213A1 (en) 2015-07-12 2018-03-08 Hangzhou Dac Biotech Co., Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
KR20220147720A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
WO2023033129A1 (ja) 2021-09-03 2023-03-09 東レ株式会社 癌の治療及び／又は予防用医薬組成物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
DE69230824T2 (de) * 1991-08-09 2000-07-27 Teikoku Hormone Mfg Co Ltd Neue tetrapeptidderivate
US5533097A (en) * 1992-02-26 1996-07-02 Motorola, Inc. Portable communication system comprising a local and wide area communication units which can store a communication when the wide area communication system is not available
AU3777593A (en) 1992-02-26 1993-09-13 Paul C. Clark System for protecting computers via intelligent tokens or smart cards
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
UA45304C2 (uk) * 1992-05-20 2002-04-15 Басф Аг Похідні пептиду або їх солі, фармацевтична композиція
AU679479B2 (en) * 1992-12-16 1997-07-03 Basf Aktiengesellschaft Dolostatin analog
US5554993A (en) 1994-01-04 1996-09-10 Panasonic Technologies, Inc. Global position determining system and method
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5554725A (en) * 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5663149A (en) * 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5618232A (en) 1995-03-23 1997-04-08 Martin; John R. Dual mode gaming device methods and systems
US5970143A (en) 1995-11-22 1999-10-19 Walker Asset Management Lp Remote-auditing of computer generated outcomes, authenticated billing and access control, and software metering system using cryptographic and other protocols
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
AU728161B2 (en) 1997-01-10 2001-01-04 Silicon Gaming, Inc. Method and apparatus using geoographical position and a universal time to determination means to provide authenticated, secure, on-line communication between remote gaming locations
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6554705B1 (en) 1997-08-22 2003-04-29 Blake Cumbers Passive biometric customer identification and tracking system
US6629591B1 (en) 2001-01-12 2003-10-07 Igt Smart token
US6438382B1 (en) 2001-02-14 2002-08-20 Telefonaktiebolaget Lm Ericsson (Publ.) Expedited location determination in analog service areas

Also Published As

Publication number Publication date
KR100579748B1 (ko) 2006-05-15
AU750120B2 (en) 2002-07-11
ATE314387T1 (de) 2006-01-15
NO326827B1 (no) 2009-02-23
BG65212B1 (bg) 2007-07-31
CZ2000176A3 (en) 2001-06-13
EP0991658A1 (en) 2000-04-12
ZA986358B (en) 2000-01-17
US6143721A (en) 2000-11-07
CY1107047T1 (el) 2012-09-26
PT991658E (pt) 2006-05-31
ID24669A (id) 2000-07-27
IL133784A0 (en) 2001-04-30
TW533217B (en) 2003-05-21
PL338144A1 (en) 2000-09-25
RU2195462C2 (ru) 2002-12-27
TR200103545T2 (tr) 2002-06-21
NO20000231L (no) 2000-01-17
DE69832982T2 (de) 2006-08-24
HUP0004234A3 (en) 2001-08-28
CO4990967A1 (es) 2000-12-26
US20060270606A1 (en) 2006-11-30
JP2001515010A (ja) 2001-09-18
IL133784A (en) 2005-09-25
PL197884B1 (pl) 2008-05-30
JP2012211164A (ja) 2012-11-01
US20030153505A1 (en) 2003-08-14
US20100099843A1 (en) 2010-04-22
AU8475898A (en) 1999-02-10
WO1999003879A1 (en) 1999-01-28
CN1268636C (zh) 2006-08-09
EP0991658B1 (en) 2005-12-28
BR9810911A (pt) 2000-08-01
HUP0004234A2 (hu) 2001-05-28
JP2009137967A (ja) 2009-06-25
US7662786B2 (en) 2010-02-16
US20130046077A1 (en) 2013-02-21
KR20010021998A (ko) 2001-03-15
DK0991658T3 (da) 2006-05-15
HK1029125A1 (en) 2001-03-23
CA2296036A1 (en) 1999-01-28
HRP980397A2 (en) 1999-04-30
DE69832982D1 (de) 2006-02-02
JP5122429B2 (ja) 2013-01-16
US6458765B1 (en) 2002-10-01
JP2009137968A (ja) 2009-06-25
BG104089A (en) 2000-12-29
US8163698B2 (en) 2012-04-24
CA2296036C (en) 2007-05-01
JP4508413B2 (ja) 2010-07-21
CZ303045B6 (cs) 2012-03-07
ES2258819T3 (es) 2006-09-01
SK286581B6 (sk) 2009-01-07
US7084110B2 (en) 2006-08-01
SK187999A3 (en) 2000-09-12
MY135057A (en) 2008-01-31
NZ502296A (en) 2002-02-01
CN1264388A (zh) 2000-08-23
TR200000132T2 (tr) 2000-05-22
JP5047935B2 (ja) 2012-10-10
HU228996B1 (hu) 2013-07-29
NO20000231D0 (no) 2000-01-17

Similar Documents

Publication Publication Date Title
AR018501A1 (es) Derivados de la dolastatina 15
GEP20012413B (en) Novel Substituted Cyclic Amino Acids as Pharmaceutical Agents
MX9305444A (es) Derivados de rodanina como agentes hipoglucemicos y para el tratamiento de la enfermedad de alzheimer, composiciones farmaceuticas que los contienen y procedimiento para su preparacion.
DE69030100D1 (de) Peptidderivat, verfahren zu dessen herstellung, sowie dieses enthaltende pharmazeutische zusammensetzung
DE3851776T2 (de) Verwendung von IGF-II zur Behandlung von Knochenkrankheiten.
AR011957A1 (es) Derivados de dolastatina 15 con funcionalidades carbonilo y heterociclicas en el c-terminal
DE60126980D1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
BR0213139A (pt) Composto, método de tratamento ou prevenção de doenças e de preparação de um composto, uso de um composto e composição farmacêutica
PA8432901A1 (es) Compuestos de piridilpirrol
UY28279A1 (es) Fenacilo 2 -hidroxi - 3 - diaminoalcanos
MX9200894A (es) Composiciones terapeuticas para proteger y resucitar las celulas de mamiferos y metodos para preparar y usar las mismas.
BR9607965A (pt) Composto composição farmacêutica e processo para tratar uma doença parasítica em um mamífero
PT94982A (pt) Processo para a preparacao de peptidos com accao antagonista contra bradiquinina e de composicoes farmaceuticas que os contem
RU95111308A (ru) Производные 2-амино-4-фенил-4-оксомасляной кислоты, способы получения, фармацевтическая композиция
CO5640064A2 (es) Citomodilacion de peptidos para tratar cistitis intersticial
DE69125216D1 (de) Aminoalkanesulfonsäurederivate und pharmazeutische Zusammensetzungen davon zur Prävention oder Behandlung von Herzerkrankungen
ES2147629T3 (es) Guanidinas de acido alquenilcarboxilico sustituidas con un grupo fluorofenilo como inhibidores del intercambio de na+/nh+, su procedimiento de preparacion y su uso como medicamento o agente diagnostico asi como el medicamento que las contiene.
ES2149403T3 (es) Benciloxicarbonilguanidinas sustituidas como inhibidores del intercambiador de protones de sodio, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como medicamento que las contiene.
DE69818823D1 (de) Dipohosphonsäuresalze für die behandlung von osteoporose
BR0110396A (pt) Métodos para prevenir e tratar alopecia induzida por quimioterapia ou radioterapia
DK160316C (da) Analogifremgangsmaade til fremstilling af beta-casomorphinanaloge peptider samt pharmakologisk acceptable syreadditionssalte og metalkomplekser deraf
EA200001029A1 (ru) Производные гигромицина
UY26911A1 (es) Ácidos amino (oxo) acéticos inhibidores de la proteina tirosina fosfatasa
MX9300203A (es) Compuestos policiclicos disubstituidos y composicion farmaceutica que los contiene.
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.

Legal Events

Date Code Title Description
FG Grant, registration